Design and synthesis of isoxazole containing bioisosteres of epibatidine as potent nicotinic acetylcholine receptor agonists

Chemical and Pharmaceutical Bulletin

Volumn 47, Issue 10, 1999, Pages 1501-1505

  Singh, Satendra ^a,c   Avor, Kwasi S ^a   Pouw, Buddy ^a   Seale, Thomas W ^b   Basmadjian, Garo P ^a  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c Peninsula Laboratories Inc   (United States)

Author keywords

Binding affinity; Epibatidine; Isoxazole isosteres; Toxicity

Indexed keywords

2 (3 METHYL 5 ISOXAZOLYL) 7 AZABICYCLO[2.2.1]HEPTANE; 2 (3 PHENYL 5 ISOXAZOLYL) 7 AZABICYCLO[2.2.1]HEPTANE; 2 (5 ISOXAZOLYL) 7 AZABICYCLO[2.2.1]HEPTANE; EPIBATIDINE; NICOTINIC AGENT; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; DRUG CONFORMATION; DRUG DESIGN; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; LD 50; NONHUMAN; RAT; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION;

EID: 0032711770     PISSN: 00092363     EISSN: None     Source Type: Journal    
DOI: 10.1248/cpb.47.1501     Document Type: Article

References (22)

1. Spande T. F., Garraffo H. M., Edwards M. W., Yeh H. J. C., Pannell L., Daly J. W., J. Am. Chem. Soc., 114, 3475-3478 (1992).
2. a) Badio B., Daly J. W., Mol. Pharmacol., 45, 563-569 (1994);
3. b) Quian C., Li T. Shen T. Y., Libertine-Graham L., Eckman J., Biftu T., Ip S., Eur. J. Pharmacol., 250, R13-R14 (1993);
4. c) Damaj M. I., Creasy K. R., Grove A. D., Rosecrans J. A., Martin B. R., Brain Res., 664, 34-40 (1994);
5. d) Sullivan J. P., Decker M. W., Brioni J. D., Donnelly-Roberts D., Anderson D. J., Bannon A. W., Kang C. H., Adams P., Piattoni-Kaplan M., Buckley M. J., Gopalkrishnan M., Williams M., Arneric S. P., J. Pharmacol. Exp. Ther., 271, 624-631 (1994).
6. Fisher M., Huangfu D., Shen T. Y., Guyenet P. G., J. Pharmacol. Exp. Ther., 270, 702-707 (1994).
7. Bonhaus D. W., Bley K. R., Broka C. A., Fontana D. J., Leung E., Lewis R., Sheih, A., Wong E. H. F., J. Pharmacol. Exp. Ther., 272, 1199-1203 (1995).
8. McDonald I. A., Cosford N., Vernier J.-M., Ann. Reports Med. Chem., 30, 41-50 (1995).
9. Holladay M. W., Dart M. J., Lynch J. K., J. Med. Chem., 40, 4169-4194 (1997).
10. Patani G. A., LaVoie E. J., Chem. Rev., 96, 3147-3176 (1996).
11. Basmadjian G. P., Singh S., Avor K. S., Pouw B., Seale T. W., "Pain Mechanisms and Management," ed. by Ayrapetyan S. N., Apkarian A. V, IOS Press, Netherlands, 1998, pp. 285-300.
12. Arneric S. P., Sullivan J. P., Briggs C. A., Donnelly-Roberts D., Anderson D. J., Raszkiewicz J. L., Hughes M. L., Cadman E. D., Adams P., Garvey D. S., Wasicak J. T., Williams M., J. Pharmacol. Exp. Ther., 270, 310-318 (1994).
13. Chen Z., Trudell M. L., Chem. Rev., 96, 1179-1193 (1996).
14. Singh S., Basmadjian G. P., Tetrahedron Lett., 38, 6829-6830 (1997).
15. a) Kotian P., Abraham P., Lewin A. H., Mascarella S. W., Boja J. W., Kuhar M. J., Carroll F. I., J. Med. Chem., 38, 3451-3453 (1995);
16. b) Elliott R. L., Kopecka H., Lin N.-H., He Y., Garvey D. S., Synthesis, 1995, 772-774.
17. Badio B., Garraffo H. M., Plummer C. V., Padgett W. L., Daly J. W., Eur. J. Pharmacol., 321, 189-194 (1997).
18. Beers W. H., Reich E., Nature (London), 228, 917-922 (1970).
19. Sheridan R. P., Nilakantan R., Dixon J. S., Venkataraghavan R., J. Med. Chem., 29, 899-906 (1986).
20. Glennon R. A., Herndon J. L., Dukat M., Med. Chem. Res., 4, 461-473 (1994).
21. Abreo M. A., Lin N-H., Garvey D. S., Gunn D. E., Hettinger A.-M., Wasicak J. T., Pavlik P. A., Martin Y. C., Donnelly-Roberts D. L., Anderson D. J., Sullivan J. P., Williams M., Arneric S. P., Holladay M. W., J. Med. Chem., 39, 817-825 (1996).
22. Pabreza L. A., Dhawan S., Kellar K. J., Mol. Pharmacol., 39, 9-12 (1991).